Evidence map›Paper›PMID 36952073›Full record

ReviewEJNMMI radiopharmacy and chemistry2023

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Oliver C Kiss, Peter J H Scott, Martin Behe, Ivan Penuelas, Jan Passchier, Ana Rey, Marianne Patt, Silvio Aime, Amir Jalilian, Peter Laverman and 11 more

Full text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Oliver C KissHelmholtz Zentrum Dresden Rossendorf, Dresden, Germany. o.kiss@hzdr.de.ORCID http://orcid.org/0000-0001-7431-0026
Peter J H ScottUniversity of Michigan, Ann Arbor, MI, USA.
Martin BehePaul Scherrer Institute, Villigen, Switzerland.
Ivan PenuelasUniversity Clinic of Navarra, Pamplona, Spain.
Jan PasschierInvicro, Imperial College London, London, UK.
Ana ReyUniversidad de la Rebublica, Montevideo, Uruguay.
Marianne PattUniversity of Leipzig, Leipzig, Germany.
Silvio AimeUniversity of Torino, Turin, Italy.
Amir JalilianIAEA, Vienna, Austria.
Peter LavermanRadboud University Medical Center, Nijmegen, The Netherlands.
Zhen ChengShanghai Institute of Materia Medica, Shanghai, China.
Alain Faivre ChauvetInserm, Nantes, France.
Jonathan EngleUniversity of Wisconsin, Madison, WI, USA.
Frederik CleerenKatholieke Universiteit, Leuven, Belgium.
Hua ZhuPeking University Cancer Hospital, Beijing, China.
Johnny VercouillieUniversity of Tours, Tours, France.
Michael van DamUCLA, Los Angeles, USA.
Ming Rong ZhangNIRS, Chiba, Japan.
Lars PerkRadboud University Medical Center, Nijmegen, The Netherlands.
Benjamin GuilletCERIMED, Marseille, France.
Francisco AlvesUniversity of Coimbra, Coimbra, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. MAIN BODY: This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field, and include new PET-labelling methods for

Indexed as

Highlight articlesNuclear medicineRadiochemistryRadiopharmaceutical SciencesRadiopharmacyTrends in radiopharmaceutical sciences

Identifiers

PMID36952073
PMCPMC10036721

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read1
identifiers read2
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.